Symbols / ARDS $0.00 +0.00% Aridis Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • PNK
ARDS Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Vu L. Truong Ph.D.
Exch · Country PNK · United States
Market Cap 8.91K
Enterprise Value 4.81M
Income -1.14M
Sales 22.36M
FCF (ttm) -16.39M
Book/sh -0.27
Cash/sh 0.00
Employees 37
Insider 10d —
IPO Aug 14, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S 0.00
P/B -0.00
P/C —
EV/EBITDA -13.87
EV/Sales 0.21
Quick Ratio 0.03
Current Ratio 0.23
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.02
EPS next Y -0.09
EPS Growth —
Revenue Growth 4.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-11-03
Earnings (prior) 2023-11-03
ROA -4.40%
ROE —
ROIC —
Gross Margin 23.28%
Oper. Margin -208.39%
Profit Margin -5.11%
Shs Outstand 44.57M
Shs Float 40.31M
Insider Own 0.00%
Instit Own 11.44%
Short Float 6.80%
Short Ratio 0.22
Short Interest 2.00M
52W High 0.05
vs 52W High -99.60%
52W Low 0.00
vs 52W Low 100.00%
Beta 3,599.34
Impl. Vol. —
Rel Volume 0.00
Avg Volume 6.50K
Volume 10.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.00
Price $0.00
Change 0.00%
About

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-6.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-11-06 reit HC Wainwright & Co. Buy → Buy $2
2023-10-20 main HC Wainwright & Co. Buy → Buy $2
2023-01-26 main HC Wainwright & Co. — → Buy $10
2022-08-16 down Maxim Group Buy → Hold —
2021-07-20 main HC Wainwright & Co. — → Buy $19
2020-05-15 reit HC Wainwright & Co. — → Buy $11
2020-02-19 init Roth Capital — → Buy $18
2019-12-30 init HC Wainwright & Co. — → Buy $7
2018-09-10 init Northcoast Research — → Outperform $40
2018-09-10 init Laidlaw & Co. — → Buy $23
2018-09-10 init Cantor Fitzgerald — → Overweight $25
News
RSS: Latest ARDS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-06-24 TRUONG VU Chief Executive Officer — 714,286 $0.07 $50,000
2024-06-24 PATZER ERIC Director — 714,286 $0.07 $50,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
Operating Revenue
0.00
0.00
Operating Expense
29.99
-29.78%
42.71
Research And Development
25.92
-29.82%
36.94
Selling General And Administration
7.16
-2.04%
7.31
General And Administrative Expense
7.16
-2.04%
7.31
Other Gand A
7.16
-2.04%
7.31
Other Operating Expenses
-3.09
-101.37%
-1.53
Total Expenses
29.99
-29.78%
42.71
Operating Income
-29.99
+29.78%
-42.71
Total Operating Income As Reported
-29.99
+29.78%
-42.71
EBITDA
-29.51
+30.21%
-42.28
Normalized EBITDA
-29.51
+31.38%
-43.00
Reconciled Depreciation
0.49
+11.95%
0.43
EBIT
-29.99
+29.78%
-42.71
Total Unusual Items
0.00
-100.00%
0.72
Total Unusual Items Excluding Goodwill
0.00
-100.00%
0.72
Special Income Charges
0.00
-100.00%
0.72
Other Special Charges
—
-0.72
Net Income
-30.37
+28.02%
-42.19
Pretax Income
-30.37
+28.02%
-42.19
Net Non Operating Interest Income Expense
-0.12
+50.61%
-0.24
Net Interest Income
-0.12
+50.61%
-0.24
Other Income Expense
-0.26
-133.68%
0.76
Other Non Operating Income Expenses
-0.26
-726.83%
0.04
Tax Rate For Calcs
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
-30.37
+28.02%
-42.19
Net Income From Continuing Operation Net Minority Interest
-30.37
+28.02%
-42.19
Net Income From Continuing And Discontinued Operation
-30.37
+28.02%
-42.19
Net Income Continuous Operations
-30.37
+28.02%
-42.19
Normalized Income
-30.37
+29.23%
-42.91
Net Income Common Stockholders
-30.37
+34.43%
-46.32
Otherunder Preferred Stock Dividend
0.00
-100.00%
4.13
Diluted EPS
-1.62
+57.92%
-3.85
Basic EPS
-1.62
+57.92%
-3.85
Basic Average Shares
18.78
+52.77%
12.29
Diluted Average Shares
18.78
+52.77%
12.29
Diluted NI Availto Com Stockholders
-30.37
+34.43%
-46.32
Earnings From Equity Interest
—
0.00
Total Other Finance Cost
0.12
-50.61%
0.24
Line Item Trend 2022-12-31 2021-12-31
Total Assets
14.70
-45.16%
26.80
Current Assets
11.63
-52.33%
24.39
Cash Cash Equivalents And Short Term Investments
4.88
-73.06%
18.10
Cash And Cash Equivalents
4.88
-73.06%
18.10
Receivables
1.24
+423.21%
0.24
Accounts Receivable
1.00
0.00
Other Receivables
0.24
+1.27%
0.24
Prepaid Assets
3.34
+23.74%
2.70
Current Deferred Assets
1.99
+0.97%
1.97
Restricted Cash
0.18
-86.82%
1.39
Total Non Current Assets
3.07
+27.56%
2.41
Net PPE
2.15
+58.22%
1.36
Gross PPE
4.19
+42.42%
2.94
Accumulated Depreciation
-2.04
-28.90%
-1.58
Properties
0.00
0.00
Machinery Furniture Equipment
0.00
-100.00%
0.03
Construction In Progress
—
0.00
Other Properties
3.66
+53.26%
2.39
Leases
0.53
+0.00%
0.53
Goodwill And Other Intangible Assets
0.02
-22.73%
0.02
Other Intangible Assets
0.02
-22.73%
0.02
Non Current Deferred Assets
0.08
-18.75%
0.10
Other Non Current Assets
0.83
-11.17%
0.93
Total Liabilities Net Minority Interest
38.93
-2.45%
39.91
Current Liabilities
36.90
+10.65%
33.35
Payables And Accrued Expenses
11.87
+1.44%
11.70
Payables
2.31
-55.95%
5.24
Accounts Payable
2.31
-55.95%
5.24
Current Accrued Expenses
9.56
+47.96%
6.46
Current Debt And Capital Lease Obligation
4.84
+595.11%
0.70
Current Debt
4.30
+517.82%
0.70
Current Capital Lease Obligation
0.54
0.00
Current Deferred Liabilities
20.17
-3.19%
20.84
Current Deferred Revenue
20.17
-3.19%
20.84
Other Current Liabilities
0.01
-86.36%
0.11
Total Non Current Liabilities Net Minority Interest
2.03
-69.06%
6.56
Long Term Debt And Capital Lease Obligation
1.29
-75.54%
5.28
Long Term Debt
—
5.28
Long Term Capital Lease Obligation
1.29
0.00
Non Current Deferred Liabilities
0.74
-19.28%
0.91
Non Current Deferred Revenue
0.74
-19.28%
0.91
Other Non Current Liabilities
—
0.36
Stockholders Equity
-24.23
-84.84%
-13.11
Common Stock Equity
-24.23
-84.84%
-13.11
Capital Stock
0.00
+50.00%
0.00
Common Stock
0.00
+50.00%
0.00
Preferred Stock
0.00
0.00
Share Issued
27.03
+52.72%
17.70
Ordinary Shares Number
27.03
+52.72%
17.70
Additional Paid In Capital
166.38
+9.33%
152.18
Retained Earnings
-195.67
-18.37%
-165.29
Gains Losses Not Affecting Retained Earnings
5.05
0.00
Total Equity Gross Minority Interest
-24.23
-84.84%
-13.11
Total Capitalization
-24.23
-209.56%
-7.83
Working Capital
-25.27
-182.12%
-8.96
Invested Capital
-19.93
-179.47%
-7.13
Total Debt
6.13
+2.54%
5.98
Capital Lease Obligations
1.83
0.00
Net Tangible Assets
-24.25
-84.66%
-13.13
Tangible Book Value
-24.25
-84.66%
-13.13
Current Notes Payable
4.30
+517.82%
0.70
Line Item Trend 2022-12-31 2021-12-31
Operating Cash Flow
-29.13
-26.99%
-22.94
Cash Flow From Continuing Operating Activities
-29.13
-26.99%
-22.94
Net Income From Continuing Operations
-30.37
+28.02%
-42.19
Depreciation Amortization Depletion
0.49
+11.95%
0.43
Depreciation And Amortization
0.49
+11.95%
0.43
Other Non Cash Items
0.35
-94.83%
6.78
Stock Based Compensation
1.48
-34.30%
2.25
Asset Impairment Charge
0.23
0.00
Operating Gains Losses
—
-0.72
Change In Working Capital
-1.30
-112.35%
10.52
Change In Receivables
-1.00
-865.65%
0.13
Changes In Account Receivables
-1.00
0.00
Change In Prepaid Assets
0.21
+19.10%
0.18
Change In Payables And Accrued Expense
0.26
-96.76%
8.00
Change In Accrued Expense
3.19
-40.34%
5.35
Change In Payable
-2.93
-210.47%
2.65
Change In Account Payable
-2.93
-210.47%
2.65
Change In Other Working Capital
-0.84
-139.13%
2.15
Change In Other Current Assets
0.10
+85.71%
0.06
Change In Other Current Liabilities
-0.03
0.00
Investing Cash Flow
-0.08
+84.53%
-0.53
Cash Flow From Continuing Investing Activities
-0.08
+84.53%
-0.53
Net PPE Purchase And Sale
-0.08
+84.53%
-0.53
Purchase Of PPE
-0.08
+84.53%
-0.53
Capital Expenditure
-0.08
+84.53%
-0.53
Financing Cash Flow
14.78
-57.43%
34.72
Cash Flow From Continuing Financing Activities
14.78
-57.43%
34.72
Net Issuance Payments Of Debt
3.20
-36.00%
5.00
Issuance Of Debt
5.00
+0.00%
5.00
Repayment Of Debt
-1.80
0.00
Long Term Debt Issuance
5.00
+0.00%
5.00
Long Term Debt Payments
-1.80
0.00
Net Long Term Debt Issuance
3.20
-36.00%
5.00
Net Common Stock Issuance
12.61
-57.57%
29.71
Proceeds From Stock Option Exercised
0.00
-40.00%
0.01
Net Other Financing Charges
-1.03
—
Changes In Cash
-14.43
-228.19%
11.25
Beginning Cash Position
19.99
+128.88%
8.73
End Cash Position
5.56
-72.19%
19.99
Free Cash Flow
-29.21
-24.47%
-23.47
Income Tax Paid Supplemental Data
0.02
+850.00%
0.00
Common Stock Issuance
12.61
-57.57%
29.71
Earnings Losses From Equity Investments
—
0.00
Issuance Of Capital Stock
12.61
-57.57%
29.71
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category